Opportunity Information: Apply for PAR 13 185
Apply for PAR 13 185
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Image guided Drug Delivery in Cancer (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Apr 10, 2013 and posted on Apr 10, 2013.
- Applicants must submit their applications by Nov 19, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public and State controlled institutions of higher education Private institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 13-185, titled "Image Guided Drug Delivery in Cancer (R01)," is a discretionary grant program that supported R01 research projects aimed at advancing image guided drug delivery (IGDD). The core purpose was to fund innovative work that combines therapeutic delivery with imaging in a tightly integrated way, so that drug delivery can be guided in real time, monitored as it happens, and quantitatively characterized in living systems. A major emphasis was placed on validating not only whether a drug or therapeutic agent reaches its intended target, but also how much arrives, how it distributes over time, and how delivery correlates with biological response. In practice, this means projects were expected to bring together imaging technologies and drug delivery strategies to enable more precise, measurable, and responsive treatment approaches, particularly for cancer, while also allowing relevance to other diseases.
Scientifically, the FOA highlighted several priority directions. One area was the development of integrated, imaging-based platforms that can support multifunctional and multiplexed drug delivery systems. This points to work where delivery vehicles or regimens may carry multiple payloads, serve more than one function (for example, targeting plus controlled release plus reporting), or be used in combination approaches, with imaging providing the feedback loop needed to guide and optimize delivery. Another area was the creation and refinement of quantitative imaging assays that can measure drug delivery in vivo. Rather than relying on indirect or post hoc indicators, the intent was to encourage methods that produce measurable, interpretable metrics of delivery and response in living subjects. The FOA also referenced early intervention, signaling interest in approaches where imaging enables earlier detection of delivery success or treatment effect, potentially allowing therapy to be adjusted sooner and more effectively.
Administratively, this opportunity was issued by the National Institutes of Health and used the standard R01 grant mechanism. It did not require cost sharing or matching. The opportunity was posted and created on April 10, 2013, with an original and final closing date of November 19, 2015, and it was archived on December 20, 2015. It was associated with CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research), reflecting its cross-cutting focus spanning technology development, imaging/diagnostics, and therapeutic impact.
Eligibility was broad and included a wide range of domestic and international applicants. Eligible applicant types included public and state-controlled and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) organizations), for-profit organizations (including small businesses and other for-profits), independent school districts, state and local governments (state governments, county governments, city or township governments, special district governments), public housing authorities/Indian housing authorities, and federally recognized tribal governments as well as other tribal organizations. The FOA also explicitly allowed applications from non-U.S. entities and foreign institutions, and permitted foreign components of U.S. organizations as defined under NIH policy. Additional eligible categories noted included a variety of serving institutions and community-based organizations, such as HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and eligible federal government agencies.
For applicants seeking the full announcement text and official details, the FOA provided an NIH guide link (http://grants.nih.gov/grants/guide/pa-files/PAR-13-185.html). Technical access and linking support were routed through the NIH Office of Extramural Research (OER) webmaster contact (FBOWebmaster@OD.NIH.GOV).
FAQs: NIH PAR-13-185 - Image Guided Drug Delivery in Cancer (R01)
What is PAR-13-185?
PAR-13-185 is an NIH funding opportunity announcement (FOA) titled "Image Guided Drug Delivery in Cancer (R01)." It supported discretionary R01 research projects focused on image guided drug delivery (IGDD), emphasizing tight integration of therapeutic delivery with imaging.
What was the main purpose of this funding opportunity?
The core purpose was to fund innovative research that combines imaging and therapeutic delivery so drug delivery can be guided in real time, monitored as it occurs, and quantitatively characterized in living systems. A major emphasis was placed on validating whether a therapeutic reaches its intended target and measuring how much arrives, how it distributes over time, and how delivery correlates with biological response.
What does "image guided drug delivery" mean in the context of this FOA?
In this FOA, image guided drug delivery refers to approaches where imaging is not separate from therapy, but instead is used as an integrated feedback loop to guide delivery, track delivery as it happens, and quantify delivery and response in vivo (in living systems).
What research areas or scientific priorities were highlighted?
The FOA highlighted several priority directions, including: (1) developing integrated, imaging-based platforms that support multifunctional and multiplexed drug delivery systems; (2) creating and refining quantitative imaging assays to measure drug delivery in vivo; and (3) supporting early intervention approaches where imaging enables earlier detection of delivery success or treatment effect so therapy can be adjusted sooner.
What are "multifunctional and multiplexed drug delivery systems" as described here?
This refers to delivery systems or regimens that may carry multiple payloads, serve more than one function (for example, targeting plus controlled release plus reporting), or be used in combination approaches. Imaging was expected to provide feedback needed to guide and optimize these delivery strategies.
What kinds of measurements or validation did the FOA emphasize?
The FOA emphasized validating not only whether a drug or therapeutic agent reaches its intended target, but also quantifying how much arrives, how it distributes over time, and how delivery correlates with biological response, using in vivo and quantitative approaches rather than relying only on indirect or post hoc indicators.
Did the opportunity focus only on cancer?
The FOA focused particularly on cancer, but also noted relevance to other diseases, indicating that approaches could be applicable beyond oncology while still aligning with the FOA's goals.
What grant mechanism did NIH use for this FOA?
This FOA used the standard NIH R01 grant mechanism.
Was cost sharing or matching required?
No. The opportunity did not require cost sharing or matching.
When was PAR-13-185 posted and when did it close?
The opportunity was posted and created on April 10, 2013. The original closing date and final closing date were both November 19, 2015.
Is this FOA still active?
No. It was archived on December 20, 2015.
What CFDA numbers were associated with this opportunity?
The FOA was associated with CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health), 93.394 (Cancer Detection and Diagnosis Research), and 93.395 (Cancer Treatment Research).
What do the listed CFDA numbers suggest about the scope of the FOA?
Based on the CFDA numbers provided, the FOA spanned technology development and applied innovation (93.286), imaging and diagnostics related to cancer detection/diagnosis (93.394), and therapeutic impact related to cancer treatment (93.395).
Who was eligible to apply?
Eligibility was broad and included many domestic and international applicants. Eligible applicants included public and state-controlled and private institutions of higher education; nonprofits (including 501(c)(3) and certain non-501(c)(3) organizations); for-profit organizations (including small businesses and other for-profits); independent school districts; and various government entities.
What types of government organizations were eligible?
Eligible government applicants included state governments, county governments, city or township governments, special district governments, public housing authorities/Indian housing authorities, federally recognized tribal governments, other tribal organizations, U.S. territories or possessions, regional organizations, and eligible federal government agencies.
Were international (non-U.S.) organizations allowed to apply?
Yes. The FOA explicitly allowed applications from non-U.S. entities and foreign institutions.
Were foreign components of U.S. organizations allowed?
Yes. The FOA permitted foreign components of U.S. organizations as defined under NIH policy.
Did the FOA mention eligibility for specific types of serving institutions or community-based organizations?
Yes. Additional eligible categories noted included HBCUs, Hispanic-serving institutions, AANAPISIs, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations.
Where can applicants find the full FOA announcement text?
The FOA provided an NIH guide link for official details: http://grants.nih.gov/grants/guide/pa-files/PAR-13-185.html.
Who was listed for technical access or linking support?
Technical access and linking support were routed through the NIH Office of Extramural Research (OER) webmaster contact: FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Education Health
Next opportunity: NIDCD Research Career Enhancement Award for Established Investigators (K18)
Previous opportunity: Male Contraceptive Development Program (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 185
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 185) also looked into and applied for these:
| Funding Opportunity |
|---|
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) Apply for RFA MH 14 170 Funding Number: RFA MH 14 170 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21) Apply for RFA MH 14 171 Funding Number: RFA MH 14 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 190 Funding Number: PAR 13 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 13 176 Funding Number: PAR 13 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 189 Funding Number: PAR 13 189 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 177 Funding Number: PAR 13 177 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 174 Funding Number: PAR 13 174 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to R01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 172 Funding Number: PAR 13 172 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to U01 Awards on Detection of Pathogen Induced Cancer (DPIC) (U01) Apply for PAR 13 173 Funding Number: PAR 13 173 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 175 Funding Number: PAR 13 175 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 170 Funding Number: PAR 13 170 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 171 Funding Number: PAR 13 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Paul Calabresi Career Development Award for Clinical Oncology (K12) Apply for PAR 13 201 Funding Number: PAR 13 201 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R01) Apply for PA 13 210 Funding Number: PA 13 210 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Symptom Management in HIV Infected Individuals with Comorbid Conditions (R21) Apply for PA 13 211 Funding Number: PA 13 211 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Measurement Tools for Community Engaged Research Efforts (R01) Apply for PA 13 209 Funding Number: PA 13 209 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovative Measurement Tools for Community Engaged Research Efforts (R21) Apply for PA 13 212 Funding Number: PA 13 212 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Limited Competition Fogarty HIV Research Training Program for Low and Middle Income Country Institutions (D43) Apply for PAR 13 126 Funding Number: PAR 13 126 Agency: National Institutes of Health Category: Education Health Funding Amount: $282,000 |
| Medications Development Centers of Excellence Cooperative Program (U54) Apply for RFA DA 14 004 Funding Number: RFA DA 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Substance Use Disorders and Molecular Regulation of Brain Energy Utilization (R01) Apply for RFA DA 14 005 Funding Number: RFA DA 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 185", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.